AI Article Synopsis
- - The duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) has been a topic of debate for many years.
- - Advances in drug-eluting stents have decreased the incidence of major adverse cardiovascular events (MACE), leading to recommendations for shorter DAPT durations (1-3 months) for patients at high risk of bleeding.
- - The review discusses current guidelines and insights from recent clinical trials regarding DAPT duration.
Article Abstract
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) have been a debatable topic for several decades. With the newer generation drug eluting stents, risk of major adverse cardiovascular events (MACE) has significantly reduced and hence, shorter duration of DAPT (one to three months) is now recommended especially in patients with high bleeding risk. Our review highlights the current guidelines and the recommendations from the recent trials.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
dual antiplatelet
8
antiplatelet therapy
8
percutaneous coronary
8
coronary intervention
8
drug eluting
8
review short
4
short term
4
term dual
4
therapy percutaneous
4
intervention drug
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!